Synopsis
0
CEP/COS
0
VMF
0
Australia
DRUG PRODUCT COMPOSITIONS0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - TABLET;ORAL - EQ 10MG BASE
USFDA APPLICATION NUMBER - 204447
DOSAGE - TABLET;ORAL - EQ 15MG BASE **Federal...DOSAGE - TABLET;ORAL - EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 204447
DOSAGE - TABLET;ORAL - EQ 20MG BASE
USFDA APPLICATION NUMBER - 204447
DOSAGE - TABLET;ORAL - EQ 5MG BASE
USFDA APPLICATION NUMBER - 204447
Related Excipient Companies
Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pfanstiehl
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Dr. Paul Lohmann GmbH & Co. KGaA
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Clariant
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DFE Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ideal Cures
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ingredion Pharma Solutions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Keval Exports
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Neelkanth MineChem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nitika Pharmaceutical Specialities
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharmatrans-Sanaq
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Prachin Pharmachem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shijiazhuang Huaxu Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Sigachi Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Fillers, Diluents & Binders
Direct Compression
Disintegrants & Superdisintegrants
Chewable & Orodispersible Aids
Thickeners and Stabilizers
Taste Masking
Lubricants & Glidants
Co-Processed Excipients
Granulation
Coating Systems & Additives
Parenteral
Film Formers & Plasticizers
Controlled & Modified Release
Rheology Modifiers
Emulsifying Agents
Topical
Surfactant & Foaming Agents
Solubilizers
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
US Patents
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
45
PharmaCompass offers a list of Vortioxetine Hydrobromide API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Vortioxetine Hydrobromide manufacturer or Vortioxetine Hydrobromide supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Vortioxetine Hydrobromide manufacturer or Vortioxetine Hydrobromide supplier.
A vortioxetine monohydrobromide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of vortioxetine monohydrobromide, including repackagers and relabelers. The FDA regulates vortioxetine monohydrobromide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. vortioxetine monohydrobromide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of vortioxetine monohydrobromide manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A vortioxetine monohydrobromide supplier is an individual or a company that provides vortioxetine monohydrobromide active pharmaceutical ingredient (API) or vortioxetine monohydrobromide finished formulations upon request. The vortioxetine monohydrobromide suppliers may include vortioxetine monohydrobromide API manufacturers, exporters, distributors and traders.
click here to find a list of vortioxetine monohydrobromide suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A vortioxetine monohydrobromide DMF (Drug Master File) is a document detailing the whole manufacturing process of vortioxetine monohydrobromide active pharmaceutical ingredient (API) in detail. Different forms of vortioxetine monohydrobromide DMFs exist exist since differing nations have different regulations, such as vortioxetine monohydrobromide USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A vortioxetine monohydrobromide DMF submitted to regulatory agencies in the US is known as a USDMF. vortioxetine monohydrobromide USDMF includes data on vortioxetine monohydrobromide's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The vortioxetine monohydrobromide USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of vortioxetine monohydrobromide suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The vortioxetine monohydrobromide Drug Master File in Japan (vortioxetine monohydrobromide JDMF) empowers vortioxetine monohydrobromide API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the vortioxetine monohydrobromide JDMF during the approval evaluation for pharmaceutical products. At the time of vortioxetine monohydrobromide JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of vortioxetine monohydrobromide suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a vortioxetine monohydrobromide Drug Master File in Korea (vortioxetine monohydrobromide KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of vortioxetine monohydrobromide. The MFDS reviews the vortioxetine monohydrobromide KDMF as part of the drug registration process and uses the information provided in the vortioxetine monohydrobromide KDMF to evaluate the safety and efficacy of the drug.
After submitting a vortioxetine monohydrobromide KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their vortioxetine monohydrobromide API can apply through the Korea Drug Master File (KDMF).
click here to find a list of vortioxetine monohydrobromide suppliers with KDMF on PharmaCompass.
A vortioxetine monohydrobromide written confirmation (vortioxetine monohydrobromide WC) is an official document issued by a regulatory agency to a vortioxetine monohydrobromide manufacturer, verifying that the manufacturing facility of a vortioxetine monohydrobromide active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting vortioxetine monohydrobromide APIs or vortioxetine monohydrobromide finished pharmaceutical products to another nation, regulatory agencies frequently require a vortioxetine monohydrobromide WC (written confirmation) as part of the regulatory process.
click here to find a list of vortioxetine monohydrobromide suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing vortioxetine monohydrobromide as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for vortioxetine monohydrobromide API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture vortioxetine monohydrobromide as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain vortioxetine monohydrobromide and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a vortioxetine monohydrobromide NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of vortioxetine monohydrobromide suppliers with NDC on PharmaCompass.
vortioxetine monohydrobromide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of vortioxetine monohydrobromide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right vortioxetine monohydrobromide GMP manufacturer or vortioxetine monohydrobromide GMP API supplier for your needs.
A vortioxetine monohydrobromide CoA (Certificate of Analysis) is a formal document that attests to vortioxetine monohydrobromide's compliance with vortioxetine monohydrobromide specifications and serves as a tool for batch-level quality control.
vortioxetine monohydrobromide CoA mostly includes findings from lab analyses of a specific batch. For each vortioxetine monohydrobromide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
vortioxetine monohydrobromide may be tested according to a variety of international standards, such as European Pharmacopoeia (vortioxetine monohydrobromide EP), vortioxetine monohydrobromide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (vortioxetine monohydrobromide USP).
